- Home
- OPCH vs GH Comparison
OPCH vs GH Comparison
Compare OPCH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- GH
- Stock Information
- Founded
- OPCH N/A
- GH 2011
- Country
- OPCH United States
- GH United States
- Employees
- OPCH N/A
- GH N/A
- Industry
- OPCH Medical/Nursing Services
- GH Medical Specialities
- Sector
- OPCH Health Care
- GH Health Care
- Exchange
- OPCH Nasdaq
- GH Nasdaq
- Market Cap
- OPCH 5.3B
- GH 4.9B
- IPO Year
- OPCH N/A
- GH 2018
- Fundamental
- Price
- OPCH $30.68
- GH $49.77
- Analyst Decision
- OPCH Strong Buy
- GH Strong Buy
- Analyst Count
- OPCH 7
- GH 20
- Target Price
- OPCH $35.86
- GH $54.35
- AVG Volume (30 Days)
- OPCH 1.5M
- GH 2.0M
- Earning Date
- OPCH 07-30-2025
- GH 07-30-2025
- Dividend Yield
- OPCH N/A
- GH N/A
- EPS Growth
- OPCH N/A
- GH N/A
- EPS
- OPCH 1.25
- GH N/A
- Revenue
- OPCH $5,185,122,000.00
- GH $773,996,000.00
- Revenue This Year
- OPCH $13.22
- GH $23.37
- Revenue Next Year
- OPCH $8.52
- GH $21.31
- P/E Ratio
- OPCH $24.44
- GH N/A
- Revenue Growth
- OPCH 16.98
- GH 28.20
- 52 Week Low
- OPCH $21.39
- GH $20.14
- 52 Week High
- OPCH $35.53
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- OPCH 43.18
- GH 53.82
- Support Level
- OPCH $29.79
- GH $48.90
- Resistance Level
- OPCH $31.22
- GH $52.46
- Average True Range (ATR)
- OPCH 0.67
- GH 1.97
- MACD
- OPCH -0.13
- GH -0.30
- Stochastic Oscillator
- OPCH 32.48
- GH 31.78
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.